Efficacy and safety of three adefovir-based combination therapies in HBeAg-positive chronic hepatitis B patients with suboptimal response to adefovir monotherapy

Journal of Viral Hepatitis
M-L WangHong Tang

Abstract

Although high potent nucleos(t)ide analogues are strongly recommended as first-line therapy for chronic hepatitis B (CHB) in China, some patients are still being treated with adefovir disoproxil (ADV), especially those low-income patients whose health insurance could not reimburse the drug cost. Therefore, the management of patients who have failed ADV therapy or who sustained renal damage during ADV therapy remains an important clinical problem in China. This retrospective study aimed to compare the efficacy and safety of lamivudine (LAM), telbivudine (LdT) or entecavir (ETV) add-on strategies to optimize the treatment of patients with prior suboptimal response to ADV monotherapy. A total of 277 eligible patients were included in this study, and the baseline characteristics were similar among the LAM + ADV (n = 116), LdT + ADV (n = 72) and ETV + ADV (n = 89) groups. At week 96, both the proportion of undetectable HBV DNA (81.03% for LAM + ADV, 84.72% for LdT + ADV and 88.76% for ETV + ADV; P = .317) and ALT elevation (5.17% for LAM + ADV, 4.17% for LdT + ADV and 4.49% for ETV + ADV; P = 1.000) were similar among the three groups; also, a significant decline in liver stiffness was observed in each group from baseline to week 96...Continue Reading

References

Jan 5, 2006·JAMA : the Journal of the American Medical Association·Chien-Jen ChenUNKNOWN REVEAL-HBV Study Group
Apr 29, 2009·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Chien-Jen ChenUNKNOWN REVEAL-HBV Study Group
Aug 12, 2009·Hepatology International·Yun-Fan LiawUNKNOWN Chronic Hepatitis B Guideline Working Party of the Asian-Pacific Association for the Study of the Liver
Aug 29, 2009·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Anna S F Lok, Brian J McMahon
Mar 23, 2012·Journal of Hepatology·UNKNOWN European Association For The Study Of The Liver
Jan 3, 2014·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Jian SunJinlin Hou
Jun 11, 2014·World Journal of Gastroenterology : WJG·En-Qiang Chen, Hong Tang
Jul 8, 2015·Journal of Hepatology·Pietro LamperticoGeorge Papatheodoridis
Oct 16, 2015·World Journal of Hepatology·Koichi HondaKazunari Murakami
Nov 14, 2015·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Anna S F LokKhaled Mohammed
Jun 19, 2016·Current Opinion in Virology·Fabien ZoulimMassimo Levrero
Oct 16, 2016·Clinics in Liver Disease·Don C Rockey
Jan 5, 2017·Liver International : Official Journal of the International Association for the Study of the Liver·Glenda GrossiPietro Lampertico
Apr 22, 2017·Journal of Hepatology·UNKNOWN European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu, UNKNOWN European Association for the Study of the Liver

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antivirals

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.

Antivirals (ASM)

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.